Wound Management Technologies, Inc. Furthers its Government Initiatives and Business Development within the Veterans Health Administration

FORT WORTH, Texas, Sept. 29 /PRNewswire/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced today that its subsidiary, Wound Care Innovations, LLC (WCI), has entered into a partnership with Government Marketing and Procurement, LLC (GMP) of Reston, Virginia to help further WCI's business development within the Veterans Health Administration. GMP is widely recognized as a government business development leaderby technology and industry manufacturers as well as the public sector community. This engagement follows recent successes for WCI in the government sector; on September 9, 2010 the company announced that it added two more Veterans Health Administration facilities in Texas and Florida, which now means that VHA facilities in 9 states across the nation are using Cellerate RX® for treating wounds.

GMP principal retired USAF Colonel and former Deputy Surgeon General of the Air Force, Dr. Pete Demitry was quoted "This product is likely to be a game changer in the clinical treatment of wounds for a wide variety of ailments."

Ronald D. Mathis, Senior Vice President of Marketing and Sales said, "We are very excited about our partnership with GMP as we believe that with their depth of experience and relationships in the government sector, we can aggressively grow sales of our Cellerate RX® products in this space. Cellerate RX® has already made an impact in this market, and I can't think of any group more deserving of the best product in wound care management than the men and women who have served this country."

For Wound Management Technologies Shareholder Information please call 817-820-7077 or go to http://www.wmgtech.com

About GMP

Government Marketing & Procurement (GMP) provides unique market and sales strategies for its clients seeking to build and grow a footprint in the government market space. GMP leverages their deep personal network of technology and mission critical decision makers within the government and its experience with federal sales and business development management at the enterprise level. Coupled with comprehensive expertise in federal contract management and reseller sales, GMP works to develop, improve and optimize the performance and effectiveness of sales and marketing efforts in the lucrative government sector.

About Wound Care Innovations, LLC

Wound Care Innovations, LLC (WCI) is a wholly owned subsidiary of Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida. WCI markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on Cellerate RX®, please visit the WCI web site at http://www.celleraterx.com/ .

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc.'s primary focus is the distribution of its unique, patented collagen product, Cellerate RX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes. Over the past 2 years Wound Management has focused on developing evidenced-based studies on Cellerate RX® and gaining physician awareness by participation in key industry conferences. Now Wound Management is focused on expanding sales through partnerships and contracted independent representatives. Wound Management has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com, http://www.celleraterx.com, or http://www.secureehealth.com.

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

SOURCE Wound Management Technologies, Inc.